Search

Search Constraints

You searched for: Author/Creator Zhou, Shuping

Search Results

2. ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. Issue 10 (14th April 2022)

3. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. (20th April 2021)

6. Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. Issue 39 (September 2019)

8. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. (2nd April 2020)

9. RETRACTED ARTICLE: Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study. (17th November 2018)